Curcumin suppresses HIF1A synthesis and VEGFA release in pituitary adenomas

Journal of Endocrinology

Volumn 214, Issue 3, 2012, Pages 389-398

  Shan, B ^a   Schaaf, C ^a   Schmidt, A ^a   Lucia, K ^a   Buchfelder, M ^b   Losa, M ^c   Kuhlen, D ^d   Kreutzer, J ^d   Perone, M J ^e,f   Arzt, E ^e,f   Stalla, G K ^a   Renner, U ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e INSTITUTO DE FISIOLOGÍA   (Argentina)

^f Instituto de Investigación en Biomedicina de Buenos Aires   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ARTICLE; FEMALE; HUMAN; HUMAN CELL; HYPOPHYSIS ADENOMA; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CORTICOTROPHS; CURCUMIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTOTROPHS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; RATS; RNA, MESSENGER; SOMATOTROPHS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866295392     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0207     Document Type: Article

References (57)

1. Abdel-Haq H, Giacomelli S, Palmery M, Leone MG, Saso L & Silvestrini B. 2000 Aflatoxins inhibit prolactin secretion by rat pituitary cells in culture. Drug and Chemical Toxicology 23 381-386.
2. Asa SL & Ezzat S. 2009 The pathogenesis of pituitary tumors. Annual Review of Pathology 4 97-126.
3. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, Kim SR, Yun I, Bae SK & Kim KW. 2006 Curcumin inhibits hypoxia-induced angiogenesis via down- regulation of HIF-1. Oncology Reports 15 1557-1562.
4. Bangaru ML, Woodliff J, Raff H & Kansra S. 2010 Growth suppression of mouse pituitary corticotroph tumor AtT20 cells by curcumin: a model for treating Cushing's disease. PLoS ONE 5 e9893.
5. Bradford MM. 1976 A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 248-254.
6. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F & Arzt E. 2007 RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1α during hypoxia. Cell 131 309-323.
7. Carmeliet P. 2003 Angiogenesis in health and disease. Nature Medicine 9 653-660.
8. Carmeliet P. 2005 VEGF as a key mediator of angiogenesis in cancer. Oncology 69 4-10.
9. Choi H, Chun YS, Kim SW, Kim MS & Park JW. 2006 Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Molecular Pharmacology 70 1664-1671.
10. Colao A & Savastano S. 2011 Medical treatment of prolactinomas. Nature Reviews. Endocrinology 7 267-278.
11. Ebert BL & Bunn HF. 1999 Regulation of the erythropoietin gene. Blood 94 1864-1877.
12. Farnoud MR, Kujas M, Derome P, Racadot J, Peillon F & Li JY. 1994 Interactions between normal and tumoral tissues at the boundary of human pituitary adenomas. Virchows Archiv: an International Journal of Pathology 424 75-82.
13. Ferrara N. 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews 25 581-611.
14. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P & Melmed S. 2011 Current management practices for acromegaly: an international survey. Pituitary 14 125-133.
15. Gloddek J, Pagotto U, Paez-Pereda M, Arzt E, Stalla GK & Renner U. 1999 Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. Journal of Endocrinology 160 483-490.
16. Gospodarowicz D, Abraham JA & Schilling J. 1989 Isolation and characterization of a vascular cell mitogen produced by pituitary-derived folliculo stellate cells. PNAS 6 7311-7315.
17. Gupta SC, Kim JH, Prasad S & Aggarwal BB. 2010 Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer and Metastasis Reviews 29 405-434.
18. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyardasini IK & Aggarwal BB. 2011 Multitargeting by curcumin as revealed by molecular interaction studies. Natural Product Reports 28. 1937-1955.
19. Harris AL. 2002 Hypoxia - a key regulatory factor in tumour growth. Nature Reviews. Cancer 2 38-47.
20. Hickey MM & Simon MC. 2006 Regulation of angiogenesis by hypoxia and hypoxia-inducible factors. Current Topics in Developmental Biology 76 217-257.
21. Hori S, Hayashi N, Fukuoda J, Kurimoto M, Hamada H, Miyajima K, Nagai S & Endo S. 2009 Folliculostellate cell tumor in the pituitary gland. Neuropathology 29 78-80.
22. Iwaki T, Kondo A, Takeshita I, Nakagaki H, Kitamura K & Tateishi J. 1986 Proliferating potential of folliculo-stellate cells in human pituitary adenomas. Immunohistochemical and electron microscopic analysis. Acta Neuropathologica 71 233-242.
23. Jung HJ, Kim JH, Shim JS & Kwon HJ. 2010 A novel Ca2C/calmodulin antagonist HBC inhibits angiogenesis and down-regulates hypoxia-inducible factor. Journal of Biological Chemistry 285 25867-25874.
24. Kim K, Yoshida D & Teramoto A. 2005 Expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in pituitary adenomas. Endocrine Pathology 16 115-121.
25. Kunnumakkara AB, Anand P & Aggarwal BB. 2008 Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Letters 269 199-225.
26. Lafont C, Desarmenien MG, Cassou M, Molino F, Lecoq J, Hodson D, Lacampagne A, Mennessier G, El Yandouzi T, Carmignac D et al. 2010 Cellular in vivo imaging reveals coordinated regulation of pituitary microcirculation and GH cell network function. PNAS 107 4465-4470.
27. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K & Stefaneanu L. 1999 Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocrine Pathology 10 229-235.
28. Lohrer P, Gloddek J, Hopfner U, Losa M, Uhl E, Pagotto U, Stalla GK & Renner U. 2001 Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 7 95-105.
29. Masson N & Ratcliffe PJ. 2003 HIF prolyl and asparaginyl hydroxylases in the biological response to intracellular O(2) levels. Journal of Cell Science 116 3041-3049.
30. Melmed S. 2011 Pathogenesis of pituitary tumors. Nature Reviews. Endocrinology 7 257-266.
31. Miller M, Chen S, Woodliff J & Kansra S. 2008 Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells. Endocrinology 149 4158-4167.
32. Nagasawa H. 1983 The in vitro and in vivo effects of dimethyl sulfoxide on the pituitary secretion of growth hormone and prolactin in mice. Annals of the New York Academy of Sciences 411 34-42.
33. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK & Renner U. 2006 Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours. Journal of Endocrinology 191 249-261.
34. Pagotto U, Arzberger T, Theodoropoulou M, Grübler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK & Spengler D. 2000 The expression of the antiproliferative gene ZAC is lost or highly reduced in non-functioning pituitary adenomas. Cancer Research 60 6794-6799.
35. Perez-Castro C, Renner U, Haedo MR, Stalla GK & Arzt E. 2012 Cellular and molecular specificity of pituitary gland physiology. Physiological Reviews 92 1-38.
36. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R et al. 2010 Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. Journal of Clinical Endocrinology and Metabolism 95 4592-4599.
37. Renner U, Arzberger T, Pagotto U, Leingruber S, Uhl E, Müller A, Lange M, Weindl A & Stalla GK. 1998 Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically non-functioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 1368-1375.
38. Renner U, Lohrer P, Schaaf L, Feirer M, Schmitt K, Onofri C, Arzt E & Stalla GK. 2002 Transforming growth factor-β stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology 143 3759-3765.
39. Renner U, Paez-Pereda M, Arzt E & Stalla GK. 2004 Growth factors and cytokines: function and molecular regulation in pituitary adenomas. Frontiers of Hormone Research 32 96-109.
40. Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ & Petersenn S. 2007 Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. European Journal of Endocrinology 156 203-216.
41. Santos NC, Figueira-Coelho J, Martins-Silva J & Saldanha C. 2003 Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochemical Pharmacology 65 1035-1041.
42. Schaaf C, Shan B, Buchfelder M, Losa M, Kreutzer J, Rachinger W, Stalla GK, Schilling T, Arzt E, Perone MJ et al. 2009 Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Endocrine-Related Cancer 16 1339-1350.
43. Schaaf C, Shan B, Onofri C, Stalla GK, Arzt E, Schilling T, Perone MJ & Renner U. 2010 Curcumin inhibits the growth, induces apoptosis and modulates the function of pituitary folliculostellate cells. Neuroendocrinology 91 200-210.
44. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L & Panyam J. 2010 Injectable sustained release microparticles of curcumin: a new concept for cancer prevention. Cancer Research 70 4443-4452.
45. Shan B, Gerez J, Haedo M, Fuertes M, Theodoropoulou M, Buchfelder M, Losa M, Stalla GK, Arzt E & Renner U. 2012 RSUME is implicated in HIF-1-induced VEGFA production in pituitary tumour cells. Endocrine-Related Cancer 19 13-27.
46. Shehzad A, Wahid F & Lee YS. 2010 Curcumin in cancer prevention: molecular targets, pharmacokinetics, bioavailability, and clinical targets. Archiv der Pharmazie 9 489-499.
47. Shih SC & Claffey KP. 2001 Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 19 19-34.
48. Ströfer M, Jelkmann W & Depping R. 2011 Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells. The role of HIF. Strahlentherapie und Onkologie 187 393-400.
49. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E & Giannakakou P. 2008 EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7 2409-2417.
50. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL & Wass J. 2000 Angiogenesis in pituitary adenomas and the normal pituitary gland. Journal of Clinical Endocrinology and Metabolism 85 1159-1162.
51. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I et al. 2003 Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. Journal of Endocrinological Investigation 26 23-28.
52. Vidal S, Horvath E, Kovacs K, Kuroki T, Lloyd RV & Scheithauer BW. 2003 Expression of hypoxia-inducible factor-1α (HIF-1α) in pituitary tumours. Histology and Histopathology 18 679-686.
53. Wahl O, Oswald M, Tretzel L, Herres E, Arend J & Efferth T. 2011 Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Current Medicinal Chemistry 18 3136-3155.
54. Webb JD, Coleman ML & Pugh CW. 2009 Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cellular and Molecular Life Sciences 66 3539-3554.
55. Wei W & Yu XD. 2007 Hypoxia-inducible factors: cross-talk between their protein stability and protein degradation. Cancer Letters 257 145-156.
56. Yadav VR & Aggarwal BB. 2011 Curcumin: a component of the golden spice, targets multiple angiogenic pathways. Cancer Biology & Therapy 11 236-241.
57. Yuan Y, Hilliard G, Ferguson T & Millhorn DE. 2003 Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-α. Journal of Biological Chemistry 278 15911-15916.